恒生港股通创新药指数是ETF跟踪的指数中首批"纯度"达100%的创新药指数，精准汇聚港股创新药领军 企业；中证创新药产业指数则聚焦于A股创新药赛道，由不超过50家主营业务涵盖创新药研发的龙头公 司组成，在当前政策与产业趋势双重利好下，指数成分股有望持续受益于行业高质量发展。 近期创新药板块资金布局意愿强烈，11月以来，全市场创新药相关ETF合计净流入超80亿元，一定程度 上反映出市场对板块投资价值的青睐。 政策面上，首版"商保创新药目录"将于12月初正式发布，为创新药支付开辟了重要渠道；产业层面，中 国创新药"出海"势头迅猛，2025年1-10月License-out总金额已突破千亿美元，同比增速超190%，交易覆 盖了ADC、双抗等多个前沿技术领域。 分析指出，中国在全球创新药BD交易中的项目数占比已从2019年的3%跃升至2024年的13%，金额占比 从1%提升至28%，显示了中国创新药企强劲的全球竞争力。 恒生创新药ETF（159316）与创新药ETF易方达（516080）分别跟踪上述指数，为投资者提供了便捷布 局前沿创新药企业的工具。 （文章来源：每日经济新闻） ...

（责任编辑：董萍萍 ） 9月以来，创新药持续调整，估值回落到较为合理区间。进入四季度，BD交易落地重回密集发布周 期，且当前位于ESMO后（欧洲肿瘤内科学会年会）数据披露与MNC谈判接洽节点，创新药行情有望 重新迎来修复。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 风险提示：不构成个股投资建议，指数涨跌不代表未来。观点随市场环境变化，不构成投资建议。 提及基金风险收益水平各不相同，请选择与自身风险偏好匹配的产品，谨慎投资。基金收益分配原则详 见基金法律文件。 今日，创新药震荡回调，科创创新药ETF（589720）跌超2.5%。盘中溢价交易，或有资金逢低布 局。 每日经济新闻 东吴证券表示，展望2026年，创新药仍将是投资主线。主要原因是创新药国际地位有赶超之势、 BD出海井喷式增长、市值空间大及业绩进入扭亏盈利阶段等，新一代ADC+2.0 IO及小核酸等将是创新 药重点方向。 科创创新药ETF国泰（ ...

11月17日，科兴制药发布股东询价转让计划书。股东深圳科益医药控股有限公司拟转让股份1006万股，占公司总股本的5.00%，转让原因为自身经营发展需 要，受让方为具备相应定价能力和风险承受能力的机构投资者。 11月3日，欧林生物发布公告称，公司副总经理、财务负责人谭勇先生的减持计划已经完成。根据公告，谭勇先生原持有公司股份57.14万股，占公司总股本 的0.14%。按照2025年9月5日披露的减持计划，他计划通过集中竞价交易方式减持不超过12.89万股。 11月17日，A股市场走势分化，创新药板块回调，截至14:02，"20CM创新药新物种"科创创新药ETF汇添富（589120）缩量跌近3%，板块延续回调。近20个 交易日，科创创新药ETF汇添富（589120）获资金净申购超1.1亿元！ 科创创新药ETF汇添富（589120）标的指数成分股全线回调，艾力斯、泽璟制药等跌超4%，百济神州、益方生物等跌超3%，百利天恒、君实生物等跌超 2%，荣昌生物等跌超1%，科兴制药、欧琳生物等重挫。 【科创创新药ETF汇添富（589120）标的指数前十大成分股】 | 序号 | 代码 | 名称 | 涨跌幅 | 估算权重 | | ...

资料显示，湖南九典制药股份有限公司位于湖南省长沙高新开发区麓天路28号金瑞麓谷科技园A1栋， 成立日期2001年1月19日，上市日期2017年10月10日，公司主营业务涉及医药产品的研发、生产和销 售。主营业务收入构成为：药品制剂82.47%，原料药7.65%，药用辅料6.03%，提取物及其他3.16%，技 术转让及服务0.63%，其他(补充)0.05%。 九典制药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：中药、熊去氧胆酸、医 药电商、创新药、原料药等。 11月17日，九典制药盘中下跌2.05%，截至13:45，报16.76元/股，成交1.27亿元，换手率2.04%，总市值 83.84亿元。 资金流向方面，主力资金净流出1540.57万元，特大单买入0.00元，占比0.00%，卖出538.52万元，占比 4.23%；大单买入1488.27万元，占比11.68%，卖出2490.32万元，占比19.54%。 九典制药今年以来股价跌4.99%，近5个交易日跌0.30%，近20日涨0.24%，近60日跌4.99%。 分红方面，九典制药A股上市后累计派现4.50亿元。近三年，累计派现3.46亿元。 ...

截至午间收盘，科创100指数上涨0.02%，科创综指下跌0.5%，科创板50指数下跌0.8%，科创成长指数下跌1.4%。相关产品受资金关注，Wind数据显示，科 创板50ETF（588080）上一交易日获超2亿元资金净流入。 科创综指ETF易方达 跟踪上证科创板综合指数 该指数由科创板全市场证券组成, 全面覆盖大、中、小盘风格,聚焦 人工智能、半导体、新能源、创新 药等核心前沿产业,覆盖科创板上 市的全部17个一级行业,兼具高成 长性与风险分散特征 小科创企业,电于、医约王彻、电 力设备、计算机行业合计占比超 80%,其中电子、医药生物行业占 比较高 截至午间 该指数消 0. 5 科创成长50ETF 跟踪上证科创板成长指数 该指数由科创板中营业收入与净利 润等业绩指标增长率较高的50只股 票组成,成长风格突出,业绩高增 长行业占比高,电子、医药生物行 截至午间! 该指数污 每日经济新闻 ...

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [31] Core Insights - The acquisition of Crown Bioscience International by the report's subject company,艾迪康, for a base consideration of $204 million (approximately 1.48 billion RMB), marks a strategic shift from clinical testing services to drug development, aligning with the trend of collaborative development in precision medicine [3][13] - The report emphasizes the importance of CROs possessing translational medicine capabilities to facilitate the rapid transition from preclinical biomarkers to clinical trials and diagnostic processes [3] Summary by Sections Industry Overview -艾迪康 announced the acquisition of Crown Bioscience International, a global CRO focused on oncology and immuno-oncology drug discovery and development, with the transaction expected to complete by mid-2026 [3] Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as 恒瑞医药, 百济神州, and 中国生物制药, as well as companies with significant single-product potential like 一品红 and 三生制药 [5] - It also highlights the importance of companies with leading positions in cutting-edge technology platforms, such as 东诚药业 and 远大医药, and suggests monitoring the CXO sector for stable growth in R&D investment [5] Market Performance - The pharmaceutical sector saw a 3.29% increase last week, ranking 4th among 28 industries, while the Hong Kong pharmaceutical sector rose by 6.80%, ranking 2nd among 11 industries [7][30] - The report notes that the valuation of the pharmaceutical sector is currently at 30.89 times (TTM), with a premium of 22.29% over the overall A-shares [23]

Market Performance - The Hang Seng Index and the National Enterprises Index closed at 26,572 points and 9,398 points, respectively, with weekly increases of 1.3% and 1.4%[1] - Total trading volume in Hong Kong stocks was HKD 116.49 billion, similar to the previous week's HKD 115.18 billion, indicating a cautious market sentiment[1] Sector Performance - Healthcare, real estate, consumer staples, materials, and energy sectors rose by 7.2%, 5.0%, 3.8%, 3.0%, and 2.5% respectively, while consumer discretionary, industrials, and utilities fell by 0.8%, 0.7%, and 0.1%[1] - JD Health (6618 HK) and China Resources Mixc Lifestyle (1209 HK) led the blue-chip stocks with increases of 15.6% and 12.8%, while Xinyi Solar (968 HK) and Baidu Group (9888 HK) saw declines of 6.3% and 5.9%[1] Economic Indicators - China's fixed asset investment in October decreased by 1.6%, a larger drop than September's 0.1%[3] - The industrial value-added growth for October was 4.9%, down from 6.5% in September[3] - Hong Kong's GDP grew by 3.8% year-on-year in Q3, up from 3.1% in Q2, prompting the government to raise its full-year growth forecast from 2-3% to 3.2%[3] Consumer Trends - Retail sales in October reached CNY 4.6291 trillion, with a year-on-year increase of 2.9%[4] - The new round of national subsidies and the early start of the Double 11 shopping festival contributed to the upward trend in retail sales[4] - The consumer sector in Hong Kong saw a significant rebound, with an average increase of 7.7% in new consumption stocks last week[4] Industry Developments - The healthcare index rose by 6.8%, outperforming the Hang Seng Index, with notable gains in innovative drug stocks[4] - The energy sector faced declines, particularly in the solar panel segment, with Xinyi Solar and other companies experiencing significant drops due to falling silicon prices[5] - Recent policy revisions by the National Development and Reform Commission aim to support the natural gas supply chain, benefiting downstream operators[5]

Group 1 - The core viewpoint of the news is that Guizhou Sanli's stock has experienced fluctuations, with a recent decline of 2.02% and a total market value of 5.169 billion yuan [1] - As of November 17, Guizhou Sanli's stock price is 12.64 yuan per share, with a trading volume of 56.89 million yuan and a turnover rate of 1.11% [1] - The company has seen a net outflow of main funds amounting to 4.71 million yuan, with significant selling pressure observed [1] Group 2 - For the year-to-date, Guizhou Sanli's stock price has decreased by 0.19%, while it has increased by 2.85% over the last five trading days [1] - The company's revenue composition includes 60.03% from respiratory medications, 13.75% from tonics, and 9.77% from gynecological medications [1] - As of September 30, the number of shareholders has increased to 26,300, with a decrease in average circulating shares per person by 1.96% [2] Group 3 - For the period from January to September 2025, Guizhou Sanli reported a revenue of 1.038 billion yuan, reflecting a year-on-year decrease of 28.24% [2] - The net profit attributable to the parent company for the same period was 80.787 million yuan, down 58.39% year-on-year [2] - Since its A-share listing, Guizhou Sanli has distributed a total of 362 million yuan in dividends, with 260 million yuan distributed over the past three years [3]

截至9月30日，佐力药业股东户数4.14万，较上期增加7.31%；人均流通股14562股，较上期减少6.82%。 2025年1月-9月，佐力药业实现营业收入22.80亿元，同比增长11.48%；归母净利润5.10亿元，同比增长 21.00%。 分红方面，佐力药业A股上市后累计派现14.42亿元。近三年，累计派现9.42亿元。 机构持仓方面，截止2025年9月30日，佐力药业十大流通股东中，创新药（159992）位居第八大流通股 东，持股685.49万股，相比上期增加28.07万股。南方中证1000ETF（512100）位居第十大流通股东，持 股641.72万股，相比上期减少5.88万股。中欧责任投资混合A（009872）退出十大流通股东之列。 11月17日，佐力药业盘中下跌2.05%，截至09:58，报17.23元/股，成交5874.02万元，换手率0.56%，总 市值120.85亿元。 资金流向方面，主力资金净流出627.53万元，特大单买入0.00元，占比0.00%，卖出102.60万元，占比 1.75%；大单买入949.41万元，占比16.16%，卖出1474.34万元，占比25.10%。 佐力药业今年 ...

Core Viewpoint - Renfu Pharmaceutical's stock has experienced a decline of 11.71% year-to-date, with a recent drop of 2.02% on November 17, 2023, indicating potential challenges in the market [1]. Financial Performance - For the period from January to September 2025, Renfu Pharmaceutical reported a revenue of 17.883 billion yuan, a year-on-year decrease of 6.58%, while the net profit attributable to shareholders was 1.689 billion yuan, reflecting a year-on-year growth of 6.22% [2]. - Cumulative cash dividends since the company's A-share listing amount to 3.113 billion yuan, with 1.779 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Renfu Pharmaceutical increased to 69,400, a rise of 38.71%, while the average circulating shares per person decreased by 27.91% to 22,222 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 42.1832 million shares, a decrease of 1.3907 million shares compared to the previous period [3].